(2837) Impact of Regulatory Guidelines on Therapeutic, Clinical, and Microbiological Success Rates in Uncomplicated Urinary Tract Infection: Results from a Two Phase 3 Randomized Controlled Trials of Oral Gepotidacin (EAGLE-2 and EAGLE-3)

Saturday, October 14, 2023

12:15 PM – 1:30 PM US ET

Location: Hall B + C

Co-Author(s)

Caroline R. Perry, PhD (she/her/hers)

Sr Clinical Development Director
GSK, Collegeville, PA, USA
Collegeville, Pennsylvania, United States

Thomas M. Hooton, MD (he/him/his)

Voluntary Professor of Clinical Medicine
University of Miami
Coral Gables, FL, United States
NS

Nicole E. Scangarella-Oman, MS

Scientific Director
GlaxoSmithKline plc.
Collegeville, Pennsylvania, United States
HM

Helen Millns, PhD

GSK, Stevenage, UK
Stevenage, England, United Kingdom
EJ

Emily Jarvis, MSc

GSK, Stevenage, UK
Stevenage, England, United Kingdom
JD

Jeremy Dennison, MD

GSK, Brentford, UK
Brentford, England, United Kingdom
AS

Amanda Sheets, PhD

GSK, Collegeville, PA, USA
Collegeville, Pennsylvania, United States
SJ

Salim Janmohamed, MD

GSK, Brentford, UK
Brentford, England, United Kingdom